248 related articles for article (PubMed ID: 28918400)
1. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
Kerkhof M; Tran TN; Soriano JB; Golam S; Gibson D; Hillyer EV; Price DB
Thorax; 2018 Feb; 73(2):116-124. PubMed ID: 28918400
[TBL] [Abstract][Full Text] [Related]
2. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
3. The prevalence and disease burden of severe eosinophilic asthma in Japan.
Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
[No Abstract] [Full Text] [Related]
4. Costs and resource use of mild persistent asthma patients initiated on controller therapy.
Colice GL; Yu AP; Ivanova JI; Hsieh M; Birnbaum HG; Lage MJ; Brewster C
J Asthma; 2008 May; 45(4):293-9. PubMed ID: 18446593
[TBL] [Abstract][Full Text] [Related]
5. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
[No Abstract] [Full Text] [Related]
6. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β
Pavord ID; Mathieson N; Scowcroft A; Pedersini R; Isherwood G; Price D
NPJ Prim Care Respir Med; 2017 Mar; 27(1):17. PubMed ID: 28270657
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
9. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.
Zeiger RS; Schatz M; Dalal AA; Chen W; Sadikova E; Suruki RY; Kawatkar AA; Qian L
J Allergy Clin Immunol Pract; 2017; 5(1):144-153.e8. PubMed ID: 27665383
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: Results from a large tertiary care hospital.
Shantakumar S; Ho YF; Tuan LW; Lin TM; Hershko AY; Chen YH
Asian Pac J Allergy Immunol; 2023 Dec; 41(4):325-335. PubMed ID: 33274956
[TBL] [Abstract][Full Text] [Related]
11. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
12. Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data.
Husereau D; Goodfield J; Leigh R; Borrelli R; Cloutier M; Gendron A
Allergy Asthma Clin Immunol; 2018; 14():15. PubMed ID: 29713354
[TBL] [Abstract][Full Text] [Related]
13. Healthcare costs associated with short-acting β
Attar-Zadeh D; Capstick T; Leese D; Arnetorp S; Rapsomaniki E; Da Costa KP; Maslova E; Xu Y; Gibson D; Quint JK
BJGP Open; 2023 Sep; 7(3):. PubMed ID: 36759020
[TBL] [Abstract][Full Text] [Related]
14. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
[TBL] [Abstract][Full Text] [Related]
15. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
Settipane RA; Kreindler JL; Chung Y; Tkacz J
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):564-572.e3. PubMed ID: 31494235
[TBL] [Abstract][Full Text] [Related]
16. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
17. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
20. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
